🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Ipca Laboratories Limited IPCALAB NIFTY_MIDNSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.ipca.com
Company Profile ↓
₹1,827.40
+26.69% 1Y
Mkt Cap₹46,361.91 Cr
P/E62.84
P/B5.74
Div. Yield0.34%
52W High₹1,827.40
52W Low₹1,268.70
Book Value₹317.84
EPS (TTM)₹29.08

Company Overview

Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. The company also exports its products worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.

Why Investors Should Care

Healthy Capital Returns

Return on capital employed stands at 16.4%.

Consistent Profit Growth

Net profit has compounded at 34.3% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 15.8% CAGR over the past five years.

Healthy Margins

Operating margin of 16.2% supports profitability.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.10.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹9,646.33 Cr (+7.9% YoY); net profit ₹1,141.12 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +7.9%, earnings +54.7%.
  • 5-Year Trend Long-term compounding — revenue CAGR 15.8%, profit CAGR 34.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:15.83%
1 Year:7.91%

Compounded Profit Growth

5 Years:34.28%
1 Year:54.69%

Stock Price Performance

1 Year:+26.69%
6 Months:+18.35%
3 Months:+25.04%
1 Month:+15.97%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 100% of range
₹1,268.70 ₹1,827.40
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)75.73 · Overbought
Price Performance
1M+15.97%
3M+25.04%
6M+18.35%
1Y+26.69%
Valuation vs Sector

P/E of 62.84 is above the sector median of 39.97 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 15.8% over 5 years.
  • Profit CAGR of 34.3% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 62.8.
  • RSI at 76 suggests overbought conditions.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
62.84
Industry PE
39.97
Forward P/E
27.83
PEG Ratio
-
Book Value
₹317.84
Price to Book
5.74
P/S
4.79
EV/EBITDA
23.56
Dividend Yield
0.34%

Growth (CAGR)

Revenue 5Y
15.83%
Profit 5Y
34.28%
Revenue (YoY)
7.91%
Earnings (YoY)
54.69%

Profitability & Returns

ROCE
16.38%
ROE
14.15%
ROA
9.22%
Profit Margin
11.83%
Op Margin
16.18%
Gross Margin
70.74%
EPS (Latest Qtr)
₹11.79
EPS (TTM)
₹29.08

Balance Sheet & Liquidity

Debt/Equity
0.10
Quick Ratio
1.58
Current Ratio
2.76
Debt
₹808.76 Cr
Total Assets
₹12,370.19 Cr
Current Assets
₹6,373.61 Cr
Working Capital
₹4,066.68 Cr

Ownership

Promoter Holding
45.08%
Chg in Prom Hold
0.36%
FII / Inst Holding
45.17%
Chg in FII Hold
-0.01%

Financial Snapshot

Enterprise Value
₹46,361.91 Cr
Total Revenue (TTM)
₹9,646.33 Cr
EBITDA
₹2,066.58 Cr
Free Cash Flow
₹486.02 Cr
Operating Cash Flow
₹1,141.97 Cr
Shares Outstanding
₹25.37 Cr
Gross Margin
70.74%
Payout Ratio
4.45%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 IPCALAB Ipca Laboratories Limited NIFTY_MIDNSEPHARMA 1,827.40 62.84 ₹46,361.91 Cr 0.34% 16.38% 14.15% 15.83% 34.28%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 1,512.00 Cr1,585.00 Cr2,034.00 Cr2,053.00 Cr2,033.00 Cr2,093.00 Cr--2,246.69 Cr2,308.85 Cr2,556.50 Cr2,392.50 Cr2,388.48 Cr
Cost of Revenue --------708.29 Cr691.56 Cr781.64 Cr657.90 Cr691.62 Cr
Gross Profit --------1,538.40 Cr1,617.29 Cr1,774.86 Cr1,734.60 Cr1,696.86 Cr
Operating Expenses 1,331.00 Cr1,278.00 Cr1,673.00 Cr1,722.00 Cr1,711.00 Cr1,700.00 Cr--1,209.66 Cr1,300.93 Cr1,333.27 Cr1,308.84 Cr1,320.13 Cr
Operating Income 111.00 Cr239.00 Cr271.00 Cr231.00 Cr224.00 Cr294.00 Cr--328.74 Cr316.36 Cr441.59 Cr425.76 Cr376.73 Cr
EBITDA 181.00 Cr308.00 Cr361.00 Cr331.00 Cr322.00 Cr393.00 Cr--249.63 Cr449.08 Cr514.52 Cr571.19 Cr531.79 Cr
Interest Expense 18.00 Cr31.00 Cr44.00 Cr33.00 Cr29.00 Cr24.00 Cr--21.51 Cr18.51 Cr19.61 Cr17.62 Cr20.20 Cr
Pretax Income 129.00 Cr252.00 Cr225.00 Cr289.00 Cr77.00 Cr290.00 Cr--128.00 Cr330.51 Cr391.58 Cr445.98 Cr404.45 Cr
Tax Provision 47.73 Cr85.68 Cr87.75 Cr66.47 Cr73.92 Cr89.90 Cr--62.22 Cr96.09 Cr108.08 Cr81.93 Cr95.05 Cr
Net Income 78.00 Cr164.00 Cr136.00 Cr221.00 Cr1.00 Cr199.00 Cr--67.82 Cr233.21 Cr282.57 Cr326.27 Cr299.07 Cr
Diluted EPS 3.026.425.727.092.357.58--2.679.1911.1412.8611.79

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 3,144.00 Cr2,867.00 Cr3,156.00 Cr3,258.00 Cr3,746.00 Cr4,619.00 Cr5,395.00 Cr-6,206.85 Cr7,622.41 Cr8,939.59 Cr9,646.33 Cr
Cost of Revenue --------2,407.51 Cr2,725.79 Cr2,778.55 Cr2,822.72 Cr
Gross Profit --------3,799.34 Cr4,896.62 Cr6,161.04 Cr6,823.61 Cr
Operating Expenses 2,604.00 Cr2,573.00 Cr2,705.00 Cr2,803.00 Cr3,051.00 Cr3,715.00 Cr3,843.00 Cr-3,094.58 Cr3,962.15 Cr4,832.72 Cr5,263.17 Cr
Operating Income 361.00 Cr131.00 Cr278.00 Cr277.00 Cr513.00 Cr694.00 Cr1,343.00 Cr-704.76 Cr934.47 Cr1,328.32 Cr1,560.44 Cr
EBITDA 541.00 Cr294.00 Cr451.00 Cr455.00 Cr695.00 Cr904.00 Cr1,552.00 Cr-1,051.94 Cr1,337.20 Cr1,613.89 Cr2,066.58 Cr
Interest Expense 32.00 Cr35.00 Cr27.00 Cr28.00 Cr22.00 Cr20.00 Cr12.00 Cr-45.09 Cr137.29 Cr84.93 Cr75.94 Cr
Pretax Income 361.00 Cr117.00 Cr262.00 Cr291.00 Cr546.00 Cr739.00 Cr1,389.00 Cr-745.29 Cr842.67 Cr1,131.14 Cr1,572.52 Cr
Tax Provision 101.08 Cr21.06 Cr68.12 Cr52.38 Cr103.74 Cr133.02 Cr236.13 Cr-253.36 Cr313.46 Cr343.61 Cr381.15 Cr
Net Income 254.00 Cr93.00 Cr195.00 Cr239.00 Cr442.00 Cr604.00 Cr1,141.00 Cr-471.32 Cr547.35 Cr737.68 Cr1,141.12 Cr
Diluted EPS 10.073.697.719.4917.6023.9944.9434.8518.5821.5729.08-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 3,812.00 Cr3,892.00 Cr3,960.00 Cr4,116.00 Cr4,549.00 Cr5,258.00 Cr6,066.00 Cr-8,626.43 Cr11,101.28 Cr11,760.55 Cr12,370.19 Cr
Current Assets --------5,189.27 Cr5,538.90 Cr6,268.54 Cr6,373.61 Cr
Cash & Equivalents --------1,257.85 Cr208.91 Cr167.17 Cr437.12 Cr
Inventory --------1,743.37 Cr2,471.31 Cr2,560.42 Cr2,731.00 Cr
Receivables --------989.02 Cr1,686.51 Cr1,873.82 Cr2,014.26 Cr
Total Liabilities --------2,711.11 Cr3,374.28 Cr3,372.28 Cr2,846.13 Cr
Current Liabilities --------1,805.82 Cr2,355.64 Cr2,386.22 Cr2,306.93 Cr
Long Term Debt --------651.78 Cr580.41 Cr543.24 Cr109.12 Cr
Total Debt 935.00 Cr867.00 Cr716.00 Cr628.00 Cr465.00 Cr501.00 Cr265.00 Cr-1,481.27 Cr1,438.36 Cr1,362.74 Cr808.76 Cr
Total Equity 2,208.00 Cr2,259.00 Cr2,455.00 Cr2,688.00 Cr3,122.00 Cr3,627.00 Cr4,701.00 Cr-5,842.02 Cr6,332.19 Cr6,948.45 Cr8,063.81 Cr
Shares Outstanding --------25.37 Cr25.37 Cr25.37 Cr25.37 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 468.00 Cr709.00 Cr282.00 Cr341.00 Cr501.00 Cr570.00 Cr1,090.00 Cr-805.81 Cr944.65 Cr1,321.32 Cr1,141.97 Cr
Investing Cash Flow -689.00 Cr-218.00 Cr-149.00 Cr-135.00 Cr-165.00 Cr-509.00 Cr-521.00 Cr--725.00 Cr-1,291.79 Cr-869.50 Cr-246.77 Cr
Financing Cash Flow 251.00 Cr-462.00 Cr-159.00 Cr-130.00 Cr-183.00 Cr-137.00 Cr-306.00 Cr-507.24 Cr-552.55 Cr-282.98 Cr-753.52 Cr
Capital Expenditure -675.00 Cr-246.00 Cr-135.00 Cr-135.00 Cr-179.00 Cr-293.00 Cr-359.00 Cr--494.47 Cr-411.29 Cr-775.57 Cr-655.95 Cr
Free Cash Flow -207.00 Cr463.00 Cr147.00 Cr206.00 Cr322.00 Cr277.00 Cr731.00 Cr-311.34 Cr533.36 Cr545.75 Cr486.02 Cr
Net Change in Cash 29.00 Cr29.00 Cr-26.00 Cr75.00 Cr153.00 Cr-76.00 Cr264.00 Cr-588.05 Cr-899.69 Cr168.84 Cr141.68 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------61.2%64.2%68.9%70.7%
Operating Margin % 11.5%4.6%8.8%8.5%13.7%15.0%24.9%-11.4%12.3%14.9%16.2%
Net Margin % 8.1%3.2%6.2%7.3%11.8%13.1%21.1%-7.6%7.2%8.3%11.8%
ROE % 11.5%4.1%7.9%8.9%14.2%16.7%24.3%-8.1%8.6%10.6%14.2%
ROCE % --------10.3%10.7%14.2%15.5%

Shareholding Pattern

Insiders
45.08%
Institutions
45.17%
Public Float
82.24%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for IPCALAB

Google News Wed, 03 Jun 2026

Should You Be Adding Ipca Laboratories (NSE:IPCALAB) To Your Watchlist Today? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxPUHo1SExqaVVBeEJ5dUp5UllzSXYwQXRzblcxYXdUVnprWWtwa205VFhHOWpwZm9JOURIMlBkd3dmOWVSem1JT3ZqdGs5NDk0VUprS1JlbEpWUlE4SXRXMlFSSFByU1M1M2NRb1dFYnlOUl9yMUtRc05yaVNacXRVam1zSF9UOGEya216ck…

Google News Mon, 16 Mar 2026

Top trading ideas: Buy Thermax, Ipca Labs and one other share, says analyst - Business Standard

<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxPOHpuM3ZqV21BSjNZOUZkRHM4X0tfUDRkU3RBczR6cXhObm1oY2lwR21lMDR6MXVXdG4xRW5Wc1NsRWI4ZW5wdnktei1KUWJKRWs0aF9jMWhmUDdzNXJrREFxTmRtUHc3NGxHODJQb3QtdG0xUW9Eb21Ba3QxcDJMaDNSMThkRVB2dGlNdX…

Google News hu, 25 Jun 2026

IPCALAB Outlook for the Week (July 06, 2026 – July 10, 2026) - Equitypandit

<a href="https://news.google.com/rss/articles/CBMiakFVX3lxTE0xM296dmJUZENuZWZLWkFSOUlaNFBBNURZSnRfeGNnNlB4WFVDQ1p1Y0hLTVZDQTFFTU80ZW9xV0p1LU1iWG9RYWFnTlJvU3hOeE8tVnZhZW8xTWxnckdUUHJuZnNVMTM5Tmc?oc=5" target="_blank">IPCALAB Outlook for the …

Google News Sat, 15 Nov 2025

Ipca Laboratories' (NSE:IPCALAB) 20% CAGR outpaced the company's earnings growth over the same three-year period - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxOQkRXZkp1VHoybTIyS2pxeFV0d1JwV0lHbnZneEdfb190bjhpRnB2SDMyMl85UWQ2ZG02alZ6YVdKUEVrcC1hWmlURGFmeEpNamFzeGRTQ0MxNllmN1RENTAxNFhLWGNySWN6OU9pYU5BS2cwaWFZejdSRnpXVFFPNEhodDlLZ3pOVFNGbE…

Google News Wed, 18 Feb 2026

Stocks to buy in 2026 for long term: Titagarh Rail, Ipca Lab among 5 stocks that could give 10-40% return - The Economic Times

<a href="https://news.google.com/rss/articles/CBMipwJBVV95cUxOTmwyMEg4WlJlaFJrQ0c3Nng0MUhuazlBMFJ1cER5MnVDSFZwY3BOakpFODBkX0lsX2RHdXlCcEZLbFl1LUNLd0JjSnhvZDZUc0FYVmE4dndldDNNUlhrNUladnc1UEN2VExWQWpEbmNxY1FzOHJFZUxkQld0U1dwNmJUTF85bnRieVdCbn…

Google News Sat, 03 Jan 2026

Ipca Laboratories Ltd. Share Price Today - Ipca Laboratories Ltd. Stock Price Live NSE/BSE - CNBC TV18

<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxNSlRKdXZBMkRnVno0dnA1NTU1MVN3YWhQSmNCNDRva1pQVERPdTlIc0ZTR05faDRocW9wVEJ2Y3BuUXJta3lWWU5HVHVyTmcyYUl5dVRxbFJhcjRaVXBuOVlYNmlUeTlpLUpNVDQ2Vlc4b09lUzdSLTV3cXQwOEdpMUd3?oc=5" target=…

IPCALAB — Frequently Asked Questions

What is the current share price of Ipca Laboratories Limited (IPCALAB)?

As of 2026-07-15 09:52 IST, Ipca Laboratories Limited (IPCALAB) trades at ₹1,827.40 on NSE. Its 52-week range is ₹1,268.70 to ₹1,827.40.

What is the market capitalisation of IPCALAB?

Ipca Laboratories Limited (IPCALAB) has a market capitalisation of ₹46,361.91 Cr on NSE.

What is the P/E ratio of IPCALAB?

IPCALAB trades at a trailing price-to-earnings (P/E) ratio of 62.84. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 5.74.

Does IPCALAB pay a dividend?

Ipca Laboratories Limited (IPCALAB) currently offers a dividend yield of 0.34%.

What is the return on equity (ROE) of IPCALAB?

IPCALAB has a return on equity (ROE) of 14.15%. Its return on capital employed (ROCE) is 16.38%.

Is IPCALAB a good stock to buy?

This page provides a data-driven analysis of Ipca Laboratories Limited (IPCALAB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space